The Pharma Letter’s Katie Osborne takes an in-depth look at the European Federation of Pharmaceutical Industries and Association's (EFPIA) new disclosure code and how it will work in practice 21 December 2015
The Pharma Letter's Anjali Shukla caught up with Jayant Manglik, president at Religare Securities in New Delhi to discuss the current trends in the industry. 14 December 2015
Kesios Therapeutics, a portfolio company of Imperial Innovations Group which is developing novel therapeutics for the treatment of multiple myeloma and other cancers, has closed a £19.0 million ($28.6 million) Series A funding round from a syndicate of leading venture investors including Innovations, SV Life Sciences and Abingworth. 2 December 2015
On November 6, the World Trade Organization (WTO) finally agreed, after two weeks of negotiations with the United States, to extend a waiver to allow the Least Developed Countries (LDCs) to avoid implementing intellectual property rights on pharmaceutical products. Charlotte Tillett and Kayleigh Stevenson from Stevens & Bolton LLP provide an overview. 1 December 2015
India-based Vyome Biosciences plans a regulatory filing by the end of the year with US Food and Drug Administration for its lead molecule (VB 1953), which targets the vast drug resistant acne prescription market, co-founder and chief executive N Venkat told The Pharma Letter in an exclusive interview. 30 November 2015
Cheaper generic drugs may soon be commonplace in India with the government aiming to sell around 400 medications at lower prices by this December, through its Jan Aushadhi stores. 30 November 2015
Last week’s $160 billion megamerger between US pharma giant Pfizer and Irish-based Allergan provoked a huge reaction globally. The Pharma Letter's Katie Osborne examines the deal. 30 November 2015
Amidst growing drug development and manufacturing costs, setting up globalized drug making sites has become more common among pharma companies in the last decade or so, comments Dr Nicola Davies in her monthly exclusive for The Pharma Letter. According to the Food and Drug Administration, the amount of drug imports they regulate has doubled since 2004. 26 November 2015
Following swiftly on yesterday’s news, KaloBios Pharmaceuticals announced that an investor group led by Martin Shkreli, the founder and chief executive of privately-held Turing Pharmaceuticals AG, has acquired 70% of its outstanding shares, up from 55% previously. 20 November 2015
The UK division of Japanese pharma company Takeda has appointed two new directors in a bid to drive forward its expertise in the specialty care sector. 13 November 2015
After 24 years’ service to Boehringer Ingelheim, Professor Andreas Barner will retire as chairman of the board of managing directors on June 30, 2016, and will move to the Shareholders' Committee of Boehringer Ingelheim, a family-owned German pharma major. 6 November 2015
With the US Senate launching an investigation into the steep drug price hikes, the ongoing debate on the pharmaceutical industry’s pricing mechanism is once again under the scanner. 5 November 2015
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024